Article Figures & Data
Figures
- FIGURE 1.
Structure of intact antibody and IAB2M.
- FIGURE 2.
Study schema. p.i. = after injection.
- FIGURE 3.
Serum (A) and WB clearance (B) of 89Zr-IAB2M shown in aggregate mean values of biologic (i.e., decay-corrected) activity retention. %ID = percentage injected dose.
- FIGURE 4.
Biodistribution of 89Zr-IAB2M in a patient: 10 mg of IAB2M mass (A), 20 mg of IAB2M mass (B), and 50 mg of IAB2M mass (C).
- FIGURE 5.
(A) Normal-organ uptake. (B) Lesion uptake.
- FIGURE 6.
Lesion targeting with 89Zr-IAB2M in mPC patient. (A) 99mTc-MDP bone scan shows lesions in vertebrae and ribs. (B) 18F-FDG PET scan shows uptake in left femur and faint uptake in vertebral lesions. (C) 89Zr-IAB2M imaging shows more images than bone scanning or 18F-FDG (arrows).
- FIGURE 7.
89Zr-IAB2M vs. 89Zr-J591: serum clearance (A) and lesion uptake (B).
Tables
Parameter 10 mg 20 mg 50 mg Overall mean ± SD WB biologic half-life (h) 143 (119–257) 222 (165–365) 236 (211–450) 225 ± 82 WB effective half-life (h) 51 (47–60) 58 (53–65) 59 (57–67) 57 ± 5 Serum A1 (%/L) 8 (5–14) 12 (6–23) 13 (9–16) 12 ± 5 Serum α effective half-life (h) 3.1 (1.2–5.7) 5.0 (1.9–8.0) 6.3 (2.2–8.9) 5 ± 3 Serum A2 (%/L) 18 (15–27) 18 (14–29) 18 (13–27) 19 ± 5 Serum β effective half-life (h) 19 (17–27) 22 (19–27) 28 (25–32) 24 ± 5 Data are median, with range in parentheses.
All patients Target organ Mean Minimum to maximum Cohort I mean Cohort II mean Cohort III mean Adrenals 0.53 (0.06) 0.43–0.67 0.51 (0.05) 0.57 (0.08) 0.52 (0.05) Brain 0.17 (0.04) 0.11–0.24 0.15 (0.03) 0.17 (0.04) 0.19 (0.03) Breasts 0.22 (0.03) 0.17–0.28 0.21 (0.03) 0.23 (0.04) 0.24 (0.03) Gallbladder wall 0.73 (0.11) 0.52–0.94 0.71 (0.11) 0.81 (0.11) 0.68 (0.09) Lower large intestine wall 0.49 (0.13) 0.29–0.74 0.51 (0.15) 0.49 (0.13) 0.48 (0.14) Small intestine 0.36 (0.06) 0.26–0.46 0.34 (0.06) 0.37 (0.07) 0.36 (0.05) Stomach wall 0.35 (0.05) 0.27–0.43 0.33 (0.04) 0.36 (0.06) 0.36 (0.04) Upper large intestine wall 0.45 (0.08) 0.31–0.58 0.45 (0.09) 0.46 (0.09) 0.44 (0.09) Heart wall 0.69 (0.09) 0.52–0.85 0.63 (0.06) 0.70 (0.12) 0.74 (0.04) Kidneys 1.36 (0.26) 1.02–1.87 1.30 (0.23) 1.53 (0.29) 1.26 (0.18) Liver 1.67 (0.3) 0.99–2.34 1.71 (0.24) 1.83 (0.32) 1.46 (0.24) Lungs 0.52 (0.08) 0.39–0.71 0.53 (0.05) 0.52 (0.11) 0.50 (0.08) Muscle 0.25 (0.04) 0.19–0.33 0.23 (0.03) 0.26 (0.05) 0.27 (0.03) Pancreas 0.5 (0.06) 0.4–0.63 0.47 (0.05) 0.52 (0.08) 0.50 (0.04) Red marrow 0.32 (0.05) 0.23–0.41 0.29 (0.04) 0.33 (0.07) 0.34 (0.04) Osteogenic cells 0.34 (0.07) 0.23–0.46 0.30 (0.05) 0.35 (0.09) 0.36 (0.06) Skin 0.17 (0.03) 0.12–0.23 0.16 (0.03) 0.18 (0.04) 0.18 (0.03) Spleen 0.76 (0.16) 0.49–1.14 0.71 (0.10) 0.76 (0.25) 0.80 (0.08) Testes 0.19 (0.04) 0.13–0.27 0.17 (0.04) 0.19 (0.05) 0.21 (0.04) Thymus 0.31 (0.05) 0.22–0.39 0.28 (0.03) 0.31 (0.06) 0.33 (0.04) Thyroid 0.21 (0.04) 0.15–0.3 0.19 (0.04) 0.22 (0.05) 0.24 (0.04) Urinary bladder wall 0.25 (0.05) 0.18–0.36 0.23 (0.04) 0.26 (0.06) 0.28 (0.04) Total body 0.3 (0.04) 0.23–0.37 0.28 (0.04) 0.31 (0.05) 0.31 (0.04) Effective dose equivalent (mSv/MBq) 0.54 (0.07) 0.43–0.68 0.52 (0.05) 0.57 (0.09) 0.53 (0.04) Effective dose (mSv/MBq) 0.41 (0.06) 0.3–0.51 0.40 (0.05) 0.43 (0.08) 0.41 (0.04)
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer
- Antibody Engineering for Nuclear Imaging and Radioimmunotherapy
- CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
- 11C Dosimetry Scans Should Be Abandoned
- First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
- Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies
- Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody
- Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
- A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies
- Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer
- Immune Modulation Therapy and Imaging: Workshop Report
- Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding